Goldman Sachs Analyst Rating update on Wuxi Pharmatech (Cayman) Inc.
March 9, 2015 By Joe Willams From Stafford Daily
Equity Analysts at the Goldman Sachs downgrades the rating on Wuxi Pharmatech (Cayman) Inc. (NYSE:WX). The brokerage firm has issued a Neutral rating on the shares. The shares were previously rated Conviction Buy.
Wuxi Pharmatech (Cayman) Inc. (NYSE:WX) has lost 4.86% during the past week and dropped 5.42% in the last 4 weeks. The shares are however, marginally negative as compared to the S&P 500 for the past week with a loss of 3.33%. Wuxi Pharmatech (Cayman) Inc. (NYSE:WX) has underperformed the index by 6.15% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Wuxi Pharmatech (Cayman) Inc. (NYSE:WX) recorded a 33.01% change in the short interest in the past month. The 3-month %change in short interest stands at 185.77%. A decrease in 1-month short interest eases the pressure off the stock while an increase is a negative overhang. The monthly shorted shares now measure at 0.022 times the total shares outstanding. The companys short ratio is at 3.58. A higher ratio is bearish for the counter while a low ratio eases some negative pressure. The average volume for the past 20 trading days is 668,691 shares. Volume for the last 20 trading sessions stands at 0.96% of the outstanding shares.
Wuxi Pharmatech (Cayman) Inc. (NYSE:WX) was down 7.2% or 2.95 points for the day. The opening trade was executed at $36.61 and the final trade was executed at $38.01. Between these time points, the price failed to break above $38.39 while respecting $33.69 on the lower level. The daily volume was logged at 4,520,034 shares. The counter had ended the earlier session at $40.96. The 52-week high of the stock is recorded as $42.31 while the 52-week low is registered as $29.84. With approx. 70,019,000 shares in outstanding, the company has a market cap of $2,661 million, as per the current valuation.
For more on this story go to: http://stafforddaily.com/goldman-sachs-analyst-rating-update-on-wuxi-pharmatech-cayman-inc-2/359402/





